Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets

Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma

Rewiring local immune milieu by boosting dendritic cell for pancreatic cancer treatment

Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model

Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies

CD133 mRNA-Loaded Dendritic Cell Vaccination Abrogates Glioma Stem Cell Propagation in Humanized Glioblastoma Mouse Model

Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine

Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy

Dendritic cell vaccine as an alternative to opioid analgesia in patients with advanced cervical cancer.

Dendritic Cell-Based Therapy Using LY6E Peptide with a Putative Role Against Colorectal Cancer